UBS reiterates a "buy" rating on Sinopharm Group (02096.HK) with a target price of 16.30 Hong Kong dollars.

According to the Wise Finance APP, UBS reiterated its "buy" rating on Sino Biopharmaceutical (02096.HK) in a research report released on Monday with a target price of 16.30 Hong Kong dollars. At the same time, Wall Street analysts generally gave Sino Biopharmaceutical a consensus rating of "strong buy", with an average target price of 17.77 Hong Kong dollars. Based on Sino Biopharmaceutical's latest quarterly performance as of December 31, 2025, the company achieved revenue of 4.15 billion Hong Kong dollars and a net profit of 740.4 million Hong Kong dollars for the quarter. In comparison, the company achieved revenue of 3.52 billion Hong Kong dollars and a net profit of 276.57 million Hong Kong dollars in the same period last year.